Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

What Was Tested

This randomized controlled trial paper looks at Tirzepatide in the context of psoriasis and psoriatic arthritis.

However, no large, randomized, active-controlled clinical trial has evaluated a treatment strategy that addresses both diseases simultaneously.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

This phase 3b, randomized, open-label, 52-week clinical trial was conducted at 72 sites in the US in adults with moderate to severe plaque psoriasis who have overweight with 1 or more weight-related comorbidities or obesity.

Participants were randomized (1:1) to ixekizumab plus tirzepatide or ixekizumab as adjunct to diet and exercise in both treatment arms.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

The trial started on September 30, 2024, and completed the week 36 primary end point on January 8, 2026.

Data were analyzed from January to February 2026.

What Was Measured

However, no large, randomized, active-controlled clinical trial has evaluated a treatment strategy that addresses both diseases simultaneously.

The subject headings attached to it are Tirzepatide, Obesity, Psoriasis, Overweight, Antibodies, Monoclonal, Humanized and Dermatologic Agents.

What This Means in Plain Language

The paper is a randomized and open-label study of Tirzepatide in people with psoriasis and psoriatic arthritis.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (JAMA dermatology), a journal based in United States.

More context: the Tirzepatide compound page, Psoriasis and psoriatic arthritis research.